Although Chimeric Antigen Receptor (CAR)-T cell therapy represents a paradigm shift in the treatment of certain blood cancers that do not respond to other available treatment options, major challenges remain in terms of efficacy, safety, and broad availability. One approach to address this issue is to use alternative immune cells to generate CAR-T cells. In this proposal, we focus on γδ T cells because of their unique properties. Although γδ T cells have proven to be attractive effectors for generating CAR-T cells for cancer immunotherapy, the key determinants that define successful therapeutic outcomes are much less known for δγ CAR-T cells compared to αβ CAR-T cells. This gap hinders the use of δγ CAR-T cells as a platform that can potentially be effective in situations where αβ CAR-T cells have limited activity.

Please see section “Project phases and realisation” for more information.

We are open for collaborations, if you’re interested please contact dr Anže Smole.